3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Terminated
2
Withdrawn
1
Unknown
1
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Prostatic Neoplasms
18
Neoplasm Metastasis
2
Bulbo-Spinal Atrophy, X-Linked
2
Uterine Cervical Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Small Cell Lung Carcinoma
1
Salivary Gland Neoplasms
1
Prostatic Neoplasms, Castration-Resistant
1
Prostate Cancer Metastatic Disease
1
Prostate Adenocarcinoma
1
PSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC) With Prior Exposure to One Prior ARPI Who Are Candidates for Taxane-based Chemotherapy
1
Metastatic Hormone-sensitive Prostate Cancer
1
Metastatic Castration-resistant Prostate Cancer (mCRPC)
1
Metastatic Castration-Resistant Prostate Cancer
1
Melanoma
1
Esophageal Squamous Cell Carcinoma
1
Disease
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Hepatocellular
1
Bites and Stings
1
Advanced Solid Tumor
1
Adenocarcinoma
1
Interventions
enzalutamide
5
darolutamide
4
Docetaxel
3
Prednisone
2
olaparib
1
gedatolisib
1
fludrocortisone acetate
1
cabazitaxel
1
abiraterone
1
TVB-2640
1
Radiosurgery
1
Omeprazole
1
Dexamethasone
1
Androgen Antagonists
1
Abiraterone Acetate
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Prostatic Neoplasms, Castration-Resistant
×
abiraterone
×
Clear all
NCT06863272
2026-05-15
IDeate-Prostate02
Merck Sharp & Dohme LLC
Phase 1/2
Recruiting
360 enrolled